GDF15, a divergent member of the transforming growth factor β superfamily, is an emerging biomarker comparable to FGF21, as its circulating levels are noticeably increased in various disease conditions including cancer, metabolic diseases, and aging-related disorders, as well as MetS [51]. This evidence concerns the gene FGF21 and Other metabolic disease.